This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Muñoz-Rodríguez, F-J Articles by Ordinas, A Search for Related Content PubMed PubMed Citation Articles by Muñoz-Rodríguez, F-J Articles by Ordinas, A Social Bookmarking                         What's this?

Clinical significance of acquired activated protein C resistance in patients with systemic lupus erythematosus

Systemic Autoimmune Diseases Service, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain

J-C Reverter

Department of Haemotherapy and Haemostasis, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain

J Font

Systemic Autoimmune Diseases Service, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain

D Tàssies

Department of Haemotherapy and Haemostasis, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain

G Espinosa

R Cervera

Systemic Autoimmune Diseases Service, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain

F Carmona

J Balasch

Department of Gynecology and Obstetrics, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain

M Ingelmo

Systemic Autoimmune Diseases Service, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain

A Ordinas

Department of Haemotherapy and Haemostasis, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain

Antiphospholipid antibodies (aPL) may induce acquired activated protein C resistance (acquired APCR). The role of acquired APCR in patients with systemic lupus erythematosus (SLE) is not well known. To evaluate the prevalenceof acquiredAPCR and its associationwith clinical manifestations we studied 103 consecutive SLE patients and 103 matched controls. APCR in the undiluted test and after dilution in factor V deficient plasma, factor V Leiden, protein C and S, lupus anticoagulant,and anti-cardiolipin,anti-ß₂-glycoprotein I and anti-prothrombin antibodies were determined. Factor V Leiden was found in 4% in both patients and controls.The prevalenceof acquiredAPCR was 22% for the undiluted assay and 17% in the diluted test. In SLE patients,acquired APCR was associated with aPL (39 vs 13% in undiluted assay, P=0.007; and 33 vs 7% in the diluted test, P=0.001). Arterial thromboses were found in 24% of patients with acquired APCR and in 6% of patients without (P=0.04). However, no relationship was found with venous thrombosis. Acquired APCR was also associated with pregnancy losses: miscarriages in 70% of women with acquired APCR vs 32% in those without (P=0.03). Thus, in SLE patients acquired APCR seems to be associated with increased prevalence of arterial thrombosis and pregnancy losses.

Key Words: acquired activated protein C resistance factor V Leiden • antiphospholipid antibodies • systemic lupus erythematosus • thrombosis

Lupus, Vol. 11, No. 11, 730-735 (2002)
DOI: 10.1191/0961203302lu256oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J T Merrill Antibodies and clinical features of the antiphospholipid syndrome as criteria for systemic lupus erythematosus Lupus, November 1, 2004; 13(11): 869 - 876. [Abstract] [PDF]

				J.-L. P. Brouwer, M. Bijl, N. J. G. M. Veeger, H. C. Kluin-Nelemans, and J. van der Meer The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus Blood, July 1, 2004; 104(1): 143 - 148. [Abstract] [Full Text] [PDF]